Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.00    1.80 (1.74%)
Bid:
104.40
Ask:
105.20
Spread: 0.80 (0.766%)
Market Cap: £172.14m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6049Q
Yule Catto & Co PLC
08 November 2012
 



YULE CATTO & CO PLC

 

INTERIM MANAGEMENT STATEMENT

 

Continued resilient performance; Intention to change Group name

 

Yule Catto & Co plc ("Yule Catto" or "the Group") today issues its interim management statement for the period 1 July to 8 November 2012. The Group also announces its intention to change its name to Synthomer plc.

 

Trading

 

The Group has continued to perform in line with the Board's expectations since the last update provided at the interim results in August, despite the challenging macro-economic conditions, particularly in Europe.

 

In Europe and North America, profit to date remains well ahead of prior year. This has been achieved notwithstanding year to date volumes down 10%, and an adverse translation impact of £4.5 million in the first nine months of the year due to the weaker euro. This performance reflects the continued benefits of good margin management and synergy delivery which the Group has achieved during the period. Demand remains subdued with construction related areas continuing to be particularly affected. 

 

In Asia and ROW, the non-nitrile businesses continued the positive momentum achieved in the first half. Our Nitrile business is trading in line with the guidance provided at the interim results.

 

We continue to make strong progress with synergy delivery from the PolymerLatex acquisition, and remain firmly on track to realise £19 million of synergies in the current year, a year on year improvement of £16 million. The Group continues to expect to deliver the total £25 million of targeted annual synergies by March 2013. 

 

The Group's financial position remains robust with net debt at the end of September at £160 million, down from £174 million at the half year.

 

Outlook

 

The Board's expectations remain unchanged from those stated at the half year. Full year underlying profit before tax is expected to be ahead of 2011 pro-forma of £96 million.

 

Intention to change Group name to Synthomer plc

 

Over the last 5 years the Group has been transformed from a small, diversified chemical business, of which Yule Catto was the holding company, to a much larger, focussed speciality polymer business. The Group trades under the name Synthomer across the majority of its business, and the Board has therefore decided that now is an appropriate time to reflect this in the Group's name.

 

The Group will convene an Extraordinary General Meeting in on December 4 where shareholders will be asked to approve this change. If shareholders agree to this proposal, the Group's name will be changed to Synthomer plc before the year end. A circular to this effect will be distributed to shareholders today.

 

Commenting Adrian Whitfield, Group Chief Executive, said:

 

"We are pleased to have delivered a resilient performance in difficult market conditions. The Group's strong portfolio of products and leading market positions provide an excellent platform for growth and we remain confident of continuing to deliver value for our shareholders."

 

Enquiries:

 

Adrian Whitfield, Group Chief Executive

Charles Armitstead / Rosie Oddy

David Blackwood, Group Finance Director

Pendomer Communications

Tel: 01279 442791

Tel: 020 3603 5220

 

 

The company will host a conference call for analysts at 8.00am today. Please contact Pendomer Communications on 020 3603 5220 for dial in details.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLLFFALLLDIIF
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.